| Risk of breast implant associated anaplastic large cell lymphoma (BIA-ALCL) in a cohort of 3546 women prospectively followed long term after reconstruction with textured breast … PG Cordeiro, P Ghione, A Ni, Q Hu, N Ganesan, N Galasso, A Dogan, ... Journal of Plastic, Reconstructive & Aesthetic Surgery 73 (5), 841-846, 2020 | 196 | 2020 |
| Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma AJ Moskowitz, G Shah, H Schöder, N Ganesan, E Drill, H Hancock, ... Journal of Clinical Oncology 39 (28), 3109-3117, 2021 | 160 | 2021 |
| A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas AJ Moskowitz, P Ghione, E Jacobsen, J Ruan, JH Schatz, S Noor, ... Blood, The Journal of the American Society of Hematology 138 (26), 2828-2837, 2021 | 118 | 2021 |
| T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma P Ghione, P Faruque, N Mehta-Shah, V Seshan, N Ozkaya, S Bhaskar, ... Blood advances 4 (19), 4640-4647, 2020 | 84 | 2020 |
| Lubiprostone Activates Cl− Secretion via cAMP Signaling and Increases Membrane CFTR in the Human Colon Carcinoma Cell Line, T84 M Ao, J Venkatasubramanian, C Boonkaewwan, N Ganesan, A Syed, ... Digestive diseases and sciences 56, 339-351, 2011 | 62 | 2011 |
| Regulation of miRNA-29c and its downstream pathways in preneoplastic progression of triple-negative breast cancer A Bhardwaj, H Singh, K Rajapakshe, K Tachibana, N Ganesan, Y Pan, ... Oncotarget 8 (12), 19645, 2017 | 59 | 2017 |
| Long-term safety of observation in selected women following core biopsy diagnosis of atypical ductal hyperplasia RS Menen, N Ganesan, T Bevers, J Ying, R Coyne, D Lane, C Albarracin, ... Annals of surgical oncology 24, 70-76, 2017 | 55 | 2017 |
| Annexin A1 preferentially predicts poor prognosis of basal-like breast cancer patients by activating mTOR-S6 signaling A Bhardwaj, N Ganesan, K Tachibana, K Rajapakshe, CT Albarracin, ... PLoS One 10 (5), e0127678, 2015 | 40 | 2015 |
| The combination of duvelisib, a PI3K-δ, γ inhibitor, and romidepsin is highly active in relapsed/refractory peripheral T-cell lymphoma with low rates of transaminitis: results … SM Horwitz, AJ Moskowitz, ED Jacobsen, N Mehta-Shah, MS Khodadoust, ... Blood 132, 683, 2018 | 37 | 2018 |
| Exploring the potential carcinogenic role of arsenic in gallbladder cancer N Ganesan, K Bambino, P Boffetta, I Labgaa European Journal of Cancer Prevention 29 (2), 100-109, 2020 | 28 | 2020 |
| Romidepsin and lenalidomide‐based regimens have efficacy in relapsed/refractory lymphoma: combined analysis of two phase I studies with expansion cohorts N Mehta‐Shah, MA Lunning, AJ Moskowitz, AM Boruchov, J Ruan, ... American journal of hematology 96 (10), 1211-1222, 2021 | 27 | 2021 |
| Regulation of miRNA-29c and its downstream pathways in preneoplastic progression of triple-negative breast cancer. Oncotarget, 8 (12): 19645-19660 A Bhardwaj, H Singh, K Rajapakshe, K Tachibana, N Ganesan, Y Pan, ... | 27 | 2017 |
| Final results of a phase II biomarker-driven study of ruxolitinib in relapsed and refractory T-cell lymphoma AJ Moskowitz, P Ghione, ED Jacobsen, J Ruan, JH Schatz, S Noor, ... Blood 134, 4019, 2019 | 26 | 2019 |
| The combination of duvelisib and romidepsin (dr) is highly active against relapsed/refractory peripheral T‐cell lymphoma with low rates of transaminitis: final results SM Horwitz, AJ Moskowitz, N Mehta‐Shah, ED Jacobsen, ... Hematological Oncology 39, 2021 | 24 | 2021 |
| In vitro, in vivo, and parallel phase I evidence support the safety and activity of duvelisib, a PI3K-δ, γ inhibitor, in combination with romidepsin or bortezomib in relapsed … AJ Moskowitz, R Koch, N Mehta-Shah, P Myskowski, M Kheterpal, ... Blood 130, 819, 2017 | 21 | 2017 |
| Risk of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) in a cohort of 3,546 women prospectively followed after receiving textured breast implants. P Ghione, PG Cordeiro, A Ni, Q Hu, N Ganesan, N Galasso, A Dogan, ... Journal of Clinical Oncology 37 (15_suppl), 1565-1565, 2019 | 18 | 2019 |
| Suppression of Akt-mTOR pathway-a novel component of oncogene induced DNA damage response barrier in breast tumorigenesis A Bhardwaj, D Rosen, M Liu, Y Liu, Q Hao, N Ganesan, CJ Etzel, A Gullett, ... PloS one 9 (5), e97076, 2014 | 17 | 2014 |
| TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy WT Johnson, N Ganesan, ZD Epstein-Peterson, AJ Moskowitz, RN Stuver, ... Blood Advances 7 (17), 5172-5186, 2023 | 15 | 2023 |
| Phase II study of pembrolizumab plus GVD as second-line therapy for relapsed or refractory classical Hodgkin lymphoma AJ Moskowitz, G Shah, H Schöder, N Ganesan, H Hancock, T Davey, ... Blood 136, 17-18, 2020 | 14 | 2020 |
| A phase Ib/IIa trial of the combination of romidepsin, lenalidomide and carfilzomib in patients with relapsed/refractory lymphoma shows complete responses in relapsed and … N Mehta-Shah, AJ Moskowitz, MA Lunning, P Lynch, M Scheuerman, ... Blood 130, 821, 2017 | 14 | 2017 |
